4 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Absci Corporation, ABSI
Summary: Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company's Creation(TM) Platform involved in discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Absci Corporation is based in VANCOUVER, Wash.
- Last Price: $5.54
- Price Change: $0.33, 6.33%
- Yearly Gain: 220.23%
- Market Cap: $624.83M
- P/E Ratio: -4.62
Here are 3rd party ratings for ABSI:
- TipRanks.com: Buy
- TradingView.com: Strong buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 33% (84 out of 252)
What is the sentiment on the street regarding Absci Corporation ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in ABSI or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ABSI before you decide to make any investment.
Click here for chart >>
Verastem, Inc., VSTM
Summary: Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
- Last Price: $11.82
- Price Change: $0.23, 1.98%
- Yearly Gain: 134.52%
- Market Cap: $298.99M
- P/E Ratio: -2.97
Here are 3rd party ratings for VSTM:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Top 33% (84 out of 252)
What is the sentiment on the street regarding Verastem, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in VSTM or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on VSTM before you decide to make any investment.
Click here for chart >>
Stoke Therapeutics, Inc., STOK
Summary: Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts.
- Last Price: $14.17
- Price Change: $3.88, 37.71%
- Yearly Gain: 77.57%
- Market Cap: $632.74M
- P/E Ratio: -5.83
Here are 3rd party ratings for STOK:
- TipRanks.com: Buy
- TradingView.com: Strong buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 33% (84 out of 252)
What is the sentiment on the street regarding Stoke Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Negative
- Hedge Fund signal: High Risk
If you are interested in STOK or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on STOK before you decide to make any investment.
Click here for chart >>
OrganiGram Holdings Inc., OGI
Summary: Organigram Holdings Inc. is a licensed producer of cannabis and cannabis-derived products primarily in Canada, through a wholly owned subsidiary. Organigram Holdings Inc. is based in Moncton, Canada.
- Last Price: $2.30
- Price Change: $-0.39, -14.37%
- Yearly Gain: -11.05%
- Market Cap: $215.95M
- P/E Ratio: -1.24
Here are 3rd party ratings for OGI:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 35% (89 out of 252)
What is the sentiment on the street regarding OrganiGram Holdings Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: -
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in OGI or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on OGI before you decide to make any investment.
Click here for chart >>
Thanks for reading!